Arcellx Announces Pricing of Initial Public Offering

Congrats to BioHealth Capital Region-based Arcellx on their IPO! This Maryland biotech company is working to create exciting new cell therapies that have greater potency and improved target specificity to treat cancers such as multiple myeloma, acute myeloid leukemia, and solid tumors.

GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) – Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expeenses payable by Arcellx, are expected to be approximately $123.8 million. 


Read the full article at:

More Information: